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Summary.-Leucocytes from patients with a variety of tumours including gastric,
colorectal, lung, kidney and mammary cancer, were tested in the leucocyte migration
test (LMT) against organ-related and non-organ-related tumour and foetal extracts.
The reactivity of cancer patients' leucocytes against a panel of organ-related tumour
extrActs was found to be 71-93%, depending on the tumour system tested. Cross-
reactivity with a panel of non-organ-related tumour extracts was found in 0-38% of
patients. Corresponding patterns of reactivity were obtained by testing patients'
leucocytes against human foetal organ extracts: pathological migration indices (MI)
were found in 70%0 of tests in which patients' leucocytes were reacted with organ-
related extracts, and in 16% of tests with non-organ-related extracts.
The data strongly support the concept that patients' leucocytes are sensitized to
cross-reactive foetal determinants of organ-related specificities. Furthermore, it is
proposed that foetal extracts as inducers of lymphokine production in presensitized
lymphocytes could be used efficiently and reproducibly as a source of foetal antigen,
as well as in the clinical application of the LMT procedure.
THE LEUCOCYTE migration (inhibition)
test (LMT) is considered to monitor the
sensitization of tumour-patients' lympho-
cytes to antigens probably expressed on
the tumour-cell surface. The actual nature
of the antigens eliciting the LMT reaction
is virtually unknown, since most of the
pertinent studies rely on the use of un-
fractionated extracts derived from human
tumour tissue or tumour cell lines. It
was only in breast cancer that biochemic-
ally defined substances were confronted
with tumour-bearers' leucocytes (Black et
al., 1976; Kadish et al., 1976; McCoy et al.,
1978). However, even in this condition no
unequivocal identification of the relevant
antigen was achieved.
Our approach to the identification of
the relevant antigens was determined by
a relatively common result emerging from
LMT studies in different tumour systems,
namely that the specificity of the diag-
nostic reaction is related to the organ of
tumour origin (i.e. leucocytes from patients
with a given tumour "reacted" signifi-
cantly more frequently with extracts from
tumours [autologous as well as allogeneic]
arising in the same organ than with ex-
tracts from tumours of another organ).
Leucocytes from patients with tumours
differing in histology (and/or histogenesis)
but arising in the very same organ
showed no segregation into histologically
defined reaction classes (McCoy et al.,
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1977; Zoller et al., 1980). Since cross-
reactivity in tumour immuniology is often
attributed to the re-expression of foetal
antigens, extracts from whole human
foetuses (WFE) were examined by LMT.
It was determined that WFE, but not
extracts from normal adult tissues, gave
reactivity with tumour patients' leuco-
cytes, whereas leucocytes from patients
with benign disease were essentially un-
reactive (Zoller et al., 1979). The fact that
leucocytes from patients with widely
differing tumours nevertheless reacted
with a single WFE preparation (although
only in 55-60% of cases) seemed to indi-
cate that organ-related foetal specificities
will certainly be contained in the WFE,
but only in very low concentrations. Thus,
leucocytes from patients with different
tumours may have reacted with the
corresponding organ-related antigens con-
tained in WFE. This hypothesis was tested
in the present study. Extracts from specific
foetal organs (OFE) were tested with
leucocytes from patients with correspond-
ing organ-related and organ-unrelated
tumours; other appropriate controls were
also included.
MATERIAL AND METHODS
Patients.-Blood samples, tumours and
normal tissue samples were provided by
physicians affiliated to the Department of
Surgery, University of Heidelberg, and
the Krankenhaus Rohrbach, Heidelberg*.
Tumour patients were tested pre-therapeutic-
ally (i.e. usually before surgical removal ofthe
primary tumour). No discrimination between
different stages was attempted. Data were
only included in the final analysis, when tu-
mour diagnosis was confirmed by histology.
Blood samples from healthy donors were
provided by the local blood bank. Age and
sex distribution of leucocyte donors are out-
lined in the footnote to Table II. Human
foetuses were obtained from therapeutic
abortion at the City Hospital, Nottingham.
Foetal organs were carefully dissected and
extracted immediately thereafter.
Extracts.-Tissues were finely minced with
scissors and extracted using a modification
(Zoller et al., 1977a) of the 3M KCI method
(Reisfeld & Kahan, 1970). Extracts sterilized
by filtration were adjusted to protein con-
centrations of 5, 3 and 1 mg/ml and stored at
-200C. Extracts were prepared from 5
adenocarcinomas of the stomach, 5 adeno-
carcinomas of the colon or rectum, 5 oat-cell
carcinomas of the lung, 5 hypernephromas
and from an individual specimen of non-
tumorous ("normal") gastric mucosa, colonic
mucosa, lung and skin. The gestational age of
foetuses as estimated by measurement of the
length from crown to rump was found to be
around the 12th week. One foetus (length 7-5
cm) was extracted as a whole. Six of the
foetuses (length 7-5-12 cm) were carefully
dissected into the following organs: skin,
brain, lung, gut (excluding stomach), liver,
and kidneys. Organs from 3 foetuses were
pooled and extracted as outlined above. We
thus obtained 2 batches of extract per
organ, which gave comparable results in the
test. Hence, resultsobtainedwithbothbatches
were pooled.
Blood samples.-Venous blood was collec-
ted into syringes containing 75 u heparin/ml
(Kettelhack, Minden, FRG) and processed
within 2-3 h of collection.
Direct capillary tube test.-The preparation
of leucocytes and the direct capillary-tube
procedure closely followed the description
given previously (Zoller et al., 1979). Each
patient's leucocytes were tested only once, by
using a set of extracts consisting of3 tumour
extracts, 4 OFE, 1 WFE, and-in some tests
-one normal tissue extract. Tumour and
normal tissue extracts were tested at a
protein concentration of5 and 1 mg/ml, foetal
extracts were tested at 3 and 1 mg/nil.
Test evaluation.-Migration plates were
photographed and the negatives were pro-
jected on to the screen of an AM02 graphic
analyser (Kontron GmbH, MdInchen, FRG),
which produced digital area equivalents in
arbitrary units. The migration index (MI)
was calculated from the formula
ml = meanmigration area oftestsamples
mean migration area of control samples
It has to be mentioned that our test pro-
cedure, which is characterized by high extract
* We are indebted to Prof. H. Penzholz and Drs U. Schulz, D. Zeidler and P. Drings for providing the
samples and for giving access to patients' data.
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TABLE I.-Leucocyte migration reactivity of cancer patients' leucocytes with corresponding
and non-corresponding tumour extracts. Summary of data obtained in diagnostic studies
centred around tumours of different organs (references in text)
Leucocyte
donor
(tumour
localization)
Stomach
Colorectum
Other GI local
Lung
Kidney
Breast
Other local.
Positive reactivity* with a panel of tumour extracts
from
Stomach (%)
66/77t (86)
40/63 (63)
5/18 (28)
12/32 (38)
2/9 (22)
2/25 (8)
30/97 (31)
Colon (0/)
2/10 (20)
55/59 (93)
3/23 (13)
2/34 (6)
4/19 (21)
0/15 (0)
2/78 (3)
Lung (%)
6/18 (33)
3/10 (30)
1/5 (20)
265/372 (71)
5/30 (17)
5/24 (21)
47/125 (38)
* Significant MI with 3/5 tumour extracts.
t Positive reactions per total number of patients teste(l.
1 28 of these patients are included in Table II.
concentrations and short incubation (Zoller
et al., 1977a) produced a considerable inci-
dence of migration enhancement. According
to previous dose-response experiments (Zoller
et al., 1977a, 1979) enhancement may be
attributed to low antigen concentrations or
low lymphocyte sensitization levels or both.
In the present context, MIs were classified as
"significant" irrespective of whether there
was enhancement or inhibition, significance
being defined as follows: mean migration
areas of test samples (4 replicates) had to
differ significantly from the mean migration
area of medium samples (12 replicates,
Mann-Whitney U test, P <005); the re-
sponse of the 2 extract concentrations had to
accord with predetermined dose-response
relations; MIs had to be <0 8 or > 1-2. The
significance of differences in reaction fre-
quency between different groups of patients
was ascertained by the X2-test.
RESULTS
The organ-related reactivity of cancer-
patients' leucocytes against soluble
tumour extracts is demonstrated by sum-
marizing data collected in the course of
studies concerned with gastric (Zoller et
al., 1977a), colorectal (Zoller et at., 1977b)
and lung cancer (Z6ller et al., 1980). The
difference in reaction frequencies with
corresponding tumour extracts (71-9300
of cases) and with non-corresponding
extracts (0-38% of cases) is evident and
was shown to be highly significant. These
findings, summarized in Table I, together
with the demonstration that 55-58% of
tumour patients showed significant MIs
with extracts from whole human foetuses
of gestational ages 10-22 weeks (Zoller et
al., 1979) formed the basis of the present
study. To test the hypothesis that organ-
related foetal determinants may repre-
sent the repertoire of antigens responsible
for LMT reactivity of tumour-patients'
leucocytes, a new series of patients was
examined. Leucocytes were tested by 2
different procedures:
(a) Leucocytes from patients with
tumours ofthe lung, stomach, colorectum,
kidney and testes were exposed, according
to availability, to the whole complement
of extracts, including corresponding OFE,
non-corresponding OFE, WFE, a panel of
3 tumour extracts and normal tissue
extracts. Since amounts of various ex-
tracts were limited, the total number of
patients tested (far left column in Table
II) occasionally differed from the number
of patients tested with a given extract.
(b) Leucocytes from patients with other
tumours, from patients with benign
diseases and from blood-bank donors were
tested with foetal extracts only (Table
III): this was considered to be an appro-
priate specificity control at the level of
OFE. Extensive specificity-control ex-
periments with tumour extracts and
normal tissue extracts have been pre-
viously reported (Zoller et al., 1977a,b,
1979, 1980).
Kidney (%)
27/37 (73)T
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TABLE II.-Compartson ofLMT reactivity induced byfoetal organ extracts (OFE), a whole
foetal extract, corresponding tumour extracts, and normal tissue extracts
Significant MIst with extracts from
Leucocyte,~~~~~~~~~~
Foetus
n Skin Brain Lung Gut Liver Kidney WFE
11 0/11 6/11 1/2
29 2/18 8/19 3/13 18/25 26/29 1/4 18/29
41 6/41 11/41 4/41 0/12 19/41 11/16 24/41
18 0/18 11/18 2/18 - 7/18 11/18
22 3/14 5/22 2/14 3/14 9/21 - 10/22
10 1/10 1/10 3/10 2/4 6/10 1/4 7/10
Corresp.
tumourst
6/11
23/29
19/28
13/17
5/10
Corresp.
normal
tissue P§
0/2 < 0.01§
4/29 < 0-001
< 0-001
< 0-001
6/17 n.s.
2/10 n.s.
* Characteristics of patients: cancer (excluding testicular cancer): 49 F, 72 M; mean age, 61-1 yrs, range
29-88. Testicular cancer: mean age 28 yrs, range 22-33.
t Significant MIs per total number ofpatients.
t Positive reactions per total number ofpatients tested (see Table I).
§ X2 test for the comparison of the reaction frequency with OFE of the corresponding organ V8 the sum of
the frequencies with OFE from non-corresponding organs (excluding liver).
TABLE III.-Specificity control of LMT reactivity using differentfoetal extracts
Significant MIs with foetal extracts dervied from
A.
Leucocyte donors*
(disease groups)
Cancer patients:
Melanoma
Bone
Breast
Oesophagus
Liver
Pancreas
Thyroid
Miscellaneoust
Benign disease
Nervous system
Gastrointest. system
Respiratory tract
Urogenital system
Blood-bank donors
Whole
n Skin Brain Lung Gut Liver foetus
2
3
9
2
2
4
4
4
3
11
10
10
36
2/2t
1/3
7/8
2/2
0/2
1/4
1/4
1/4
0/3
0/11
0/3
0/10
1/25
0/2
1/3
2/9
0/2
0/2
1/4
0/4
2/4
0/3
1/11
1/10
0/10
1/26
0/2
0/3
3/9
1/2
0/2
0/4
0/4
1/4
0/3
1/11
1/10
1/10
3/25
1/2
0/8
0/2
0/2
0/4
0/4
1/4
2/8
4/36
1/2
1/3
2/8
1/2
2/2
1/4
2/4
1/4
1/3
2/11
0/3
0/10
5/26
1/2
3/3
3/9
1/2
2/2
3/4
2/4
4/4
0/3
0/11
2/10
1/10
2/22
* Patients' characteristics: Cancer patients, 16 F, 14 M; mean age 56-4 yrs, range 29-94. Benign disease,
12 F, 22 M; mean age 41-3 yrs, range 17-76. Blood-bank donors, 15 F, 21 M; mean age 27-5 yrs, range
22-43.
t Significant MIs per total number ofpatients tested.
t 2 tumours of the pineal gland, 1 tumour ofthe gallbladder and 1 laryngeal tumour.
The following observations are of sig-
nificance: OFE-induced reactivity was
predominantly obtained with leucocytes
from patients with tumours of the corre-
sponding organ. This was reflected by a
significant x2 test when reaction fre-
quencies obtained from different OFEs
(excluding foetal liver extract) were com-
pared. Both batches of foetal liver ex-
tracts showed a high percentage of sig-
nificant MIs with leucocytes from most
groups of patients. Wherever OFE, WFE
and the tumour extracts were tested
simultaneously (i.e. with leucocytes from
patients with tumours of the colorectum
and the kidneys), the highest frequencies
of significant MIs were regularly observed
with corresponding OFE, though differ-
ences from WFE and corresponding
tumour extracts were not significant. It
may well be that even higher scores could
be achieved by using OFE at a protein
concentration of 5 mg/ml, which was
routine with the other types of extract.
Leucocyte-
donor*
(tumour
localization)
Lung
Colorectum
Kidney
Brain
Stomach
Testis
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Under the present conditions it was ob-
vious that some of the tumour patients
failed to show significant MIs, even when
tested with corresponding OFE or tumour
extracts. This of course limits the applic-
ability of OFE as a test reagent in clinical
diagnosis.
A surprising observation was made
with leucocytes from breast-cancer donors
(Table III) in that they showed pro-
nounced reactivity with foetal skin ex-
tracts. No other groups displayirng a high
reaction frequency were observed in tests
with other types oftumour, which may be
due to the paucity of donors in individual
tumour groups.
No additional information as to extent
and specificity of reactivity was obtained
when "significant" MIs were classified
according to inhibition or enhancement of
migration. With the groups of tumour
patients listed in Table II and in the upper
part of Table III, 0-24% of significant
MIs were found to be > 1P2; with leuco-
cytes from patients with benign disease
and from blood-bank donors, enhance-
ment amounted to 7-32% of significant
MIs. However, this trend toward a higher
proportion of enhancement with control
donors' leucocytes could not be substanti-
ated by statistical analysis, mostly be-
cause the absolute incidence of enhance-
mnent in individual groups was rather
small. It should be addedthatbothbatches
of foetal liver extracts rarely showed
enhancement (i.e. in 5 and 11% of tests
with significant MIs). Hence, the ex-
ceptional results with foetal liver extracts
could not be explained by exceptionally
high incidence of enhancement.
The data from Tables II and III were
summarized in order to reveal organ-
related and non-organ-related reactivities
most readily. As seen in Table IV, highest
reaction frequencies were obtained with
corresponding OFEs, but reaction fre-
quencies obtained with tumour extracts
and WFE were comparable. Reaction
frequencies obtained with non-correspond-
ing OFE were definitely lower, thus rein-
forcing the proposal that sensitization of
leucocytes is against antigens of a re-
stricted specificity. Tests with leucocytes
from patients with benign disease and
with blood-bank donors showed low fre-
quencies of significant MIs (see Table III)
and are not included in this summary.
DISCUSSION
Evidence from LMT analyses of human
tumours argues for organ-related antigens
triggering the immune response of the
host. This concept is strongly supported
by the present study, since we were able
to show that extracts from foetal tissues
preferentially induce organ-related re-
activity in patients' leucocytes. Similar
results were obtained previously. Wells et
al. (1973) observed delayed-type hyper-
sensitivity reactions of lung-cancer
patients on injection offoetal lung extract
(16 weeks gestational age), while no reac-
tion was observed with foetal liver
TABLE IV.-Orqan-related vs non-organ-related reactivity: summary afTable8 II and III
Significant MIs obtained with extracts from
, & 5~~~~~~~~~
Leucocyte donor*
(tumour
localization)
Brain
Lung
Colorectum
Kidney
Corresp.
foetal organ
n (%)
18 11/18t (61)
11 6/11 (55)
29 18/25 (72)
41 11/16 (69)
* Individual patients were tested with one corresponding OFE, up to 3 non-corresponding OFE, 1 WFE
and 5 tumour extracts.
t Number of significant MIs per total number of patients.
t Number of significant MIs per total number of tests (individual patients being tested with more than
one tumour extract).
Corresp.
tumour
(%)
24/55t (44)
94/145 (65)
81/140 (58)
Non-corresp.
foetal organ
(%)
2/36t (6)
0/11 (0)
14/64 (22)
21/135 (16)
Whole
foetus
(0)
11/18t (61)
4/11 (36)
18/29 (62)
24/41 (59)
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extract. Levin et al. (1975) reported a
blastogenic response of leucocytes from
patients with ovarian cancer toward
extracts from foetal and adult ovary, but
not to foetal liver nor lung extracts.
Corroboration of the notion of organ-
related reaction specificity by tumour-
patients' leucocytes in the LMT is the
major issue of the present work, using
extracts from isolated foetal organs. In
addition, the use of OFE helped us to
exclude artefacts inherent in the method.
It could for instance be possible that
organ-specific reactivity of colorectal-
cancer extracts were due to microbial
contaminants despite the care we took
to keep our extracts sterile. Since an
a priori microbial contamination of foetal
gut preparations is unlikely, data ob-
tained with these extracts help to exclude
interferences of this kind. With renal-
cancer extracts, it may be argued that
immune complexes could be present in
tumorous and non-tumorous parts of the
tissues used for extraction. We have
indeed been able to show that preformed
immune complexes can induce strong
migration inhibition under appropriate
assay conditions (S. Matzku, unpublished).
Again, this possibility is rather unlikely
with foetal kidney extracts.
However, there is still another possible
cause of organ-related reactivity in the
LMT as applied to cancer patients' leuco-
cytes. It has been demonstrated in rodents
(Martin & Martin, 1975; Pierotti &
Colna,ghi, 1976) and humans (Morton,
1971; Bloom, 1972; Rosenberg, 1977) that
sera from normal or tumour-bearing indi-
viduals often contain natural antibodies.
By absorption experiments it was demon-
strated that these may show organ-related
specificities (Martin & Martin, 1975).
Hence it could be speculated that speci-
ficity in the LMT may be generated by
natural antibodies endogenously produced
in the test, which could bind to organ-
related antigens and ultimately lead to
inhibition or enhancement of migration
(see above). This interpretation would
also apply to tests using foetal extracts.
On the basis of the present data it is not
possible to discriminate between antibody-
mediated reaction mechanisms and the
conventional interpretation of the LMT as
an in vitro analogon of the delayed type
hypersensitivity reaction.
In our study foetal liver extracts may
be an exception, in as much as both batches
induced a high frequency of significant
migration indices (mostly inhibition) with
leucocytes from tumour patients but also
(to a lesser extent) with leucocytes from
patients with benign diseases and from
blood-bank donors. The microscopic aspect
of leucocyte halos after exposure to foetal
liver extracts often suggested that these
extracts were in fact unspecifically cyto-
toxic. Yet it is noteworthy that among the
different groups, leucocytes from patients
with colorectal cancer showed an exceed-
ingly high score of significant MIs. In this
groups it may well be that "specific"
reactivity and unspecific cytotoxicity by
foetal liver extracts were superimposed.
When OFEs were tested with leucocytes
from either patients with tumours origin-
ating in non-corresponding organs or
patients with benign diseases or blood-
bank donors, we observed significant MIs
in only 0-22% of tests. This contrasted
with the high frequency of significant
MIs on interaction of OFE with leuco-
cytes from patients with tumours in the
corresponding organs. Hence, it can be
postulated that the reactivity induced by
foetal organ extracts is attributable to
their content of substances specifically
interacting with sensitized lymphocytes.
The background of reactivity in tests with
non-corresponding leucocytes, or leuco-
cytes from patients devoid of malignant
disease, may be caused either by antigens
with broad specificity or by artefactual
interactions between leucocytes and ex-
tracts. However, it has to be pointed out
that an in-depth analysisofLMTreactivity
by leucocytes from patients with selected
benign diseases possibly involving auto-
immune phenomena may reveal specific
sensitization to substances also contained
in organ-related foetal extracts. This was
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indeed observed by Marcussen & Bendixen
(1974) when leucocytes from patients with
ulcerative colitis were confronted with an
extract of foetal colon-but not with an
extract offoetal lung.
In the present study, we have used
pools of foetal tissue for extraction. How-
ever, the gestational age of foetuses varied
only between 10 and 12 weeks. This may
explain the lack of OFE-induced reac-
tivity with some patients. It is possible
that tumours of different histological
types, and even individual tumours with
similar histology, may carry antigens
which are expressed during different
phases ofgestation. Interpretations ofthis
kind have been proposed by various
authors (for references see Rees et al.,
1979) but logistic and legal difficulties
obviously prevented experimental verifi-
cation. In the mouse, evidence for phase-
specific foetal determinants being ex-
pressed on tumour cells was obtained
(Gorczynsky, 1978).
There may be other interpretations for
the occasional lack of reactivity of cancer
patients' leucocytes with corresponding
OFEs. Since migration enhancement
appears to be produced by a distinct
lymphokine (i.e. the migration-enhance-
ment factor of Weisbart et al. (1974)) it is
conceivable that under certain conditions
liberation ofinhibition factor and enhance-
ment factor may occur simultaneously,
and the counteracting effects might be
balanced. Obviously, this situation would
be misclassified as absence ofsensitization.
Furthermore, absence ofin vitro reactivity
might reflect a subthreshold level of
sensitization in vivo, which might either
be caused by negative regulation or by an
insufficient expression of antigens on the
tumour cells. Finally, technical problems
may account for a lack of reactivity (e.g.
insufficient test sensitivity, instability of
foetal antigens under extraction con-
ditions).
Two conclusions can be drawn from the
above arguments. First, widespread re-
activity of WFE in immunodiagnostic
tests such as the LMT (Albrecht et al.,
1978; Zoller et al., 1979) is not at variance
with organ-related reaction specificity of
tumour extracts. According to our initial
hypothesis, widespread cross-reactivity
could be dissected into more or less uni-
directional components by separate ex-
traction of foetal organs. Second, in con-
trast to our expectation, no qualitative
and only slight quantitative improvement
of LMT sensitivity could be achieved by
the use of OFE. Hence, even with the use
of OFE, it cannot be expected that
tumour diagnosis by the LMT will permit
prognoses with validity for the individual
patient. Yet OFE might be a useful start-
ing material for the preparation of onco-
foetal antigens.
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